Tessera to present three preclinical gene-editing studies at 2026 ASH meeting
AI Summary- Tessera Therapeutics will present three sets of new preclinical data at the 68th ASH Annual Meeting.
- Three presentations cover in vivo CAR-T generation, HBB correction and hematopoietic stem-cell editing.
- The meeting runs December 12-15, 2026, in New Orleans, Louisiana.